Physician profile
Daniel S Raskind
NPI 1518034834
$982.95
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2021: $125 · 2024: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $249.99 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $117.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $112.30 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $106.02 | 2019 | |
| Aidoc Medical Ltd | $106.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $101.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $100.00 | 2024 | Rexulti |
| Lilly USA, LLC | $90.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,582.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Raskind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.